News

BREAKING NEWS: The U.S. Food and Drug Administration has approved BridgeBio’s Attruby™ (acoramidis) for the treatment of patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Exciting news for patients with ATTR-CM (transthyretin amyloid cardiomyopathy): the FDA has approved Attruby (acoramidis), offering a...

BOSTON, Mass., Oct. 31, 2024 /PRNewswire/ -- The Amyloidosis Research Consortium (ARC) is proud to announce the launch of its Clinical Fellowship Program, designed to enhance the education and development of the next generation of amyloidosis specialists. This initiative aims...

David Gibson,1 Kristen Hsu,1 James Signorovitch,2 and Isabelle Lousada1 1Amyloidosis Research Consortium, Newton, MA, USA; 2The Analysis Group Inc., Boston, MA, USA   Amyloid transthyretin (ATTR) amyloidosis is a progressive, debilitating, and ultimately fatal disease caused by deposition of misfolded...

David Gibson, PhD, CMPP Director of Strategic Programs, Engagement, and Communications Amyloidosis Research Consortium   The Inflation Reduction Act (IRA), signed into law on August 16, 2022, tackled a wide range of issues from tax reform, energy security, environmental and...

BREAKING NEWS: The U.S. Food and Drug Administration has approved AstraZeneca and Ionis’ WAINUA™ (eplontersen) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, commonly referred to as hATTR-PN or ATTRv-PN. WAINUA™ (eplontersen) is a Ligand-Conjugated Antisense...